Design and practical evaluation of a shielded application system for intravenously administered radionuclide therapies

2020 ◽  
Vol 59 (04) ◽  
pp. 323-331
Author(s):  
Christian Kühnel ◽  
Thomas Winkens ◽  
Tobias Niksch ◽  
Julia Greiser ◽  
Steffen Schrott ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Infusion Pump ◽  
Application System ◽  
Steel Coating ◽  
Practical Evaluation ◽  
Infusion Line ◽  
Cost Efficient ◽  
Effective Radiation ◽  
Radiopharmaceutical Dose ◽  
Dose Radiation

Abstract Aim Intravenous radionuclide therapies are gaining importance. With the increased frequency of these therapies, safe application procedures in combination with effective radiation protection are needed. We present a shielded system which can be universally used for the application of liquid radiopharmaceuticals. Materials and methods The application system consists of a cuboidal box made of lead with stainless steel coating, an inner layer of polymethyl methacrylate (PMMA), a disposable line/bottle system, and a medical infusion pump. No proprietary disposable parts are used. The system was tested and validated ex-vivo, and evaluated for Lu-177 peptide receptor radionuclide and for radioligand therapies (PRRT, RLT). Results Construction of the application system was performed in accordance with the physical characteristics of the used isotopes. 10 validation procedures with 1 GBq Tc-99m-pertechnetate confirmed functionality. 38 PRRT and 13 RLT procedures were performed successfully and completely. At least 98 % of the prescribed activities were infused. No leakage of radioactivity occurred. Dose rate measurements showed that the radiation in the box is shielded completely, and that exposure arises only from the infusion line outside the box and from the patient. Conclusion The presented application system for intravenous radionuclide therapies is feasible, safe, and cost-efficient. It has been shown that Lu-177-PRRT and -RLT can be performed without complications while ensuring nearly complete infusion of the prescribed radiopharmaceutical dose. Radiation exposure of the applying physician and other staff is low. The construction of the shielding box ensures complete shielding of all radionuclides currently used for radiomolecular therapies.

Neurological Deficit after Carotid Infusion of Cisplatin and 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) for Malignant Glioma: An Analysis of Risk Factors

Neurosurgery ◽  
1986 ◽  
Vol 19 (5) ◽  
pp. 779-783 ◽  
Author(s):  
P. Kapp John ◽  
A. Sanford Robert
Keyword(s):  
Risk Factors ◽  
Neurological Deficit ◽  
Infusion Pump ◽  
Malignant Gliomas ◽  
Internal Capsule ◽  
Neurological Deficits ◽  
Infusion Therapy ◽  
Infusion Line ◽  
Permanent Neurological Deficit ◽  
Infusion Technique

Abstract The records of 24 patients with malignant gliomas treated with carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are reviewed for risk factors that might suggest the development of a permanent neurological deficit after infusion. Permanent neurological deficits were seen with doses of cisplatin as low as 69 mg/m2, although doses as high as 100 mg/m2 were tolerated by other patients. All 3 patients who developed permanent neurological deficits received fixed doses of cisplatin of 150 mg and supplied only 2 major intracranial branches from the infused carotid artery. In none of these patients was a filter used in the infusion line. Other risk factors identified in 2 of the 3 patients were diffuse neoplasm involving the region of the internal capsule and the use of an infusion pump rather than a pulsatile bolus infusion technique. The development of a permanent neurological deficit appeared unrelated to the dose of BCNU within the range utilized, and preinfusion administration of corticosteroids did not prevent neurological deficit. These possible risk factors should be considered in the future development of protocols for arterial infusion therapy of malignant gliomas.

The Effects of Multiple Infusion Line Extensions on Occlusion Alarm Function of an Infusion Pump

2009 ◽  
Vol 108 (2) ◽  
pp. 518-520 ◽  
Author(s):  
Diana Deckert ◽  
Christian Buerkle ◽  
Andreas Neurauter ◽  
Peter Hamm ◽  
Karl H. Lindner ◽  
...  
Keyword(s):  
Infusion Pump ◽  
Line Extensions ◽  
Infusion Line

Effect of low dose radiation on adhesion and apoptosis-results of an ex-vivo model

1998 ◽  
Vol 42 (1) ◽  
pp. 241 ◽  
Author(s):  
Keilholz Ludwig ◽  
Kern Peter ◽  
Christian Forster ◽  
Seegenschmidt Michael Heinrich ◽  
Sauer Rolf
Keyword(s):  
Low Dose ◽  
Ex Vivo ◽  
Low Dose Radiation ◽  
Ex Vivo Model ◽  
Dose Radiation

scholarly journals Design and Development of a Low Cost, Smart Infusion Pump to Deliver Medications for Patients using Labview Interface With Arduino

2019 ◽  
Vol 9 (1S4) ◽  
pp. 753-758
Keyword(s):  
High Risk ◽  
Adverse Events ◽  
Low Cost ◽  
Infusion Pump ◽  
Clinical Settings ◽  
Syringe Pump ◽  
Patient Controlled Analgesia ◽  
Infusion Pumps ◽  
Cost Efficient ◽  
User Friendly

An infusion pump is a medical device that delivers fluids such as nutrients into a patient’s body in controlled amount. They are widely used in clinical settings such as hospitals, nursing homes etc. There are many types of infusion pumps including large volume, patient-controlled analgesia and insulin pumps. Some are designed mainly for stationary use at a patient’s bedside, because infusion pumps are frequently used to administer critical fluids, including high-risk medications, pump failures and can have significant implications for patient’s safety. From 2005 to 2009, FDA received approximately 56,000 reports of adverse events associated with the use of infusion pumps, including numerous injuries and deaths. Some of the problems include software problems, alarm errors, inadequate design, broken components, battery failures, spark, and shock. In order to overcome these problems, our team came up with an idea to rectify. Our project is very compact in size when compared to the ordinary syringe pump. It can be lifted with single hand since it is weightless and the components used in our project are reliable, cost efficient and user friendly.

Security-Aware Service Specification for Healthcare Information Systems

2011 ◽  
pp. 1720-1725
Author(s):  
Khaled M. Khan
Keyword(s):  
Information Systems ◽  
Web Services ◽  
Healthcare System ◽  
Network Resources ◽  
Healthcare Information ◽  
Application System ◽  
Web Based ◽  
Healthcare Information Systems ◽  
Geographically Dispersed ◽  
Cost Efficient

With the rapid advancement of Web-based technologies, healthcare information systems are becoming increasingly heterogeneous in terms of their architecture, composition, and runtime characteristics. A healthcare system can be composed of several stand-alone service components, such as Web services available from various distributed sources for runtime execution. We use the terms Web services and service interchangeably in this chapter to refer to the same concept. A healthcare application system can be composed of multiple autonomous geographically dispersed software services. A healthcare software service is autonomous as it has its own executable code and uses its own data or files. The composition of a healthcare system can be dynamic or static, depending on how services are connected to each other to provide the services. Some of the services are downloaded directly from the Internet and executed dynamically with the application system. The use of independent services in the healthcare information system is appealing because it supports reusability of code and far efficient utilization of network resources, and it might be cost efficient.

Security-Aware Service Specification for Healthcare Information Systems

2008 ◽  
pp. 1236-1240 ◽  
Author(s):  
Khaled M. Khan
Keyword(s):  
Information Systems ◽  
Web Services ◽  
Healthcare System ◽  
Network Resources ◽  
Healthcare Information ◽  
Application System ◽  
Web Based ◽  
Healthcare Information Systems ◽  
Geographically Dispersed ◽  
Cost Efficient

With the rapid advancement of Web-based technologies, healthcare information systems are becoming increasingly heterogeneous in terms of their architecture, composition, and runtime characteristics. A healthcare system can be composed of several stand-alone service components, such as Web services available from various distributed sources for runtime execution. We use the terms Web services and service interchangeably in this chapter to refer to the same concept. A healthcare application system can be composed of multiple autonomous geographically dispersed software services. A healthcare software service is autonomous as it has its own executable code and uses its own data or files. The composition of a healthcare system can be dynamic or static, depending on how services are connected to each other to provide the services. Some of the services are downloaded directly from the Internet and executed dynamically with the application system. The use of independent services in the healthcare information system is appealing because it supports reusability of code and far efficient utilization of network resources, and it might be cost efficient.

scholarly journals The MEMIC: An ex vivo system to model the complexity of the tumor microenvironment

2021 ◽  
Author(s):  
Libuše Janská ◽  
Libi Anandi ◽  
Nell C. Kirchberger ◽  
Zoran S. Marinkovic ◽  
Logan T. Schachtner ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Tumor Cells ◽  
Ex Vivo ◽  
Tumor Stroma ◽  
Cell Types ◽  
Blood Stream ◽  
Direct Access ◽  
Heterogeneous Environments ◽  
Multiple Cell ◽  
Cost Efficient

ABSTRACTThere is an urgent need for accurate, scalable, and cost-efficient models of the complexity and heterogeneity of the tumor microenvironment. Here, we detail how to fabricate and use the Metabolic Microenvironment Chamber (MEMIC) – a 3D-printed ex vivo model of intratumoral heterogeneity. A major driver of the cellular and molecular diversity in tumors is the accessibility to the blood stream that provides key resources such as oxygen and nutrients. While some tumor cells have direct access to these resources, many others must survive under progressively more ischemic environments as they reside further from the vasculature. The MEMIC is designed to simulate the differential access to nutrients and allows co-culturing different cell types, such as tumor and immune cells. This system is optimized for live imaging and other microscopy-based approaches and it is a powerful tool to study tumor features such as the effect of nutrient scarcity on tumor-stroma interactions. Due to its adaptable design and full experimental control, the MEMIC can provide novel insights into the tumor microenvironment that would be difficult to obtain via other methods. As a proof of principle, we show that cells can sense gradual changes in metabolite concentration, and tune intracellular cell signaling to form multicellular spatial patterns of cell proliferation. We also show that ischemic macrophages reduce epithelial features in neighboring tumor cells highlighting the power of this system to study cell-cell interactions and non-cell autonomous effects of the metabolic microenvironment. We propose that the MEMIC can be easily adapted to study early development, ischemic stroke, and other systems where multiple cell types interact within heterogeneous environments.

scholarly journals Human skin explant model for the investigation of topical therapeutics

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jessica E. Neil ◽  
Marc B. Brown ◽  
Adrian C. Williams
Keyword(s):  
Human Skin ◽  
Ex Vivo ◽  
In Vitro Models ◽  
Animal Testing ◽  
Tissue Integrity ◽  
Human Illness ◽  
Cost Efficient ◽  
In Vivo Effects

AbstractThe development of in vitro and ex vivo models to mimic human illness is important not only for scientific understanding and investigating therapeutic approaches but also to mitigate animal testing and bridge the inter-species translational gap. While in vitro models can facilitate high-throughput and cost-efficient evaluation of novel therapeutics, more complex ex vivo systems can better predict both desirable and adverse in vivo effects. Here we describe an ex vivo cultured human skin explant model in which we have characterized pathological tissue integrity, barrier function and metabolic stability over time. Our findings suggest that human skin can be successfully cultured for pharmacodynamic use up to and beyond 9 days without any adverse physiological consequence.

Sign in / Sign up

Export Citation Format

Share Document